IGM Capex To Depreciation vs Price To Sales Ratio Analysis

IGMS Stock

USD 9.25 0.24 2.53%

IGM Biosciences financial indicator trend analysis is infinitely more than just investigating IGM Biosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether IGM Biosciences is a good investment. Please check the relationship between IGM Biosciences Capex To Depreciation and its Price To Sales Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IGM Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy IGM Stock please use our How to Invest in IGM Biosciences guide.

Capex To Depreciation vs Price To Sales Ratio

Capex To Depreciation vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of IGM Biosciences Capex To Depreciation account and Price To Sales Ratio. At this time, the significance of the direction appears to have very week relationship.

The correlation between IGM Biosciences' Capex To Depreciation and Price To Sales Ratio is 0.2. Overlapping area represents the amount of variation of Capex To Depreciation that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of IGM Biosciences, assuming nothing else is changed. The correlation between historical values of IGM Biosciences' Capex To Depreciation and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Depreciation of IGM Biosciences are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Capex To Depreciation i.e., IGM Biosciences' Capex To Depreciation and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.2

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing IGM Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on IGM Biosciences sales, a figure that is much harder to manipulate than other IGM Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from IGM Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into IGM Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IGM Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy IGM Stock please use our How to Invest in IGM Biosciences guide.At this time, IGM Biosciences' Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 152.9 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (1.50) in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	4.5M	6.1M	8.0M	8.4M
Total Operating Expenses	165.3M	229.0M	265.6M	278.9M

Reconciled Depreciation Total Operating Expenses

IGM Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other
Total Assets		0.79	0.92	-0.34	0.95	0.97	0.94	-0.79	-0.8	0.7	0.88	0.95	0.89	0.82	1.0	0.96	0.94	0.56	0.95	0.97	0.81	0.65	0.95	0.88	1.0	0.87
Other Current Liab	0.79		0.9	0.01	0.8	0.69	0.89	-0.44	-0.99	0.23	0.57	0.88	0.91	1.0	0.76	0.72	0.87	0.9	0.87	0.75	0.93	0.94	0.63	0.98	0.77	0.96
Total Current Liabilities	0.92	0.9		-0.3	0.84	0.83	0.99	-0.6	-0.89	0.46	0.72	0.98	0.99	0.91	0.89	0.86	0.97	0.75	0.89	0.89	0.88	0.82	0.77	0.93	0.9	0.92
Total Stockholder Equity	-0.34	0.01	-0.3		-0.16	-0.27	-0.3	0.3	-0.09	-0.46	-0.31	-0.3	-0.3	0.02	-0.35	-0.29	-0.22	0.12	-0.15	-0.53	-0.03	0.07	-0.37	-0.07	-0.35	-0.11
Other Liab	0.95	0.8	0.84	-0.16		0.96	0.88	-0.74	-0.82	0.69	0.83	0.91	0.8	0.82	0.94	0.96	0.89	0.52	0.98	0.87	0.78	0.62	0.94	0.89	0.94	0.91
Net Tangible Assets	0.97	0.69	0.83	-0.27	0.96		0.88	-0.85	-0.72	0.8	0.91	0.9	0.79	0.72	0.97	0.98	0.91	0.4	0.94	0.9	0.73	0.5	0.98	0.8	0.97	0.82
Property Plant And Equipment Net	0.94	0.89	0.99	-0.3	0.88	0.88		-0.66	-0.88	0.55	0.78	0.99	0.98	0.89	0.92	0.91	0.99	0.68	0.93	0.91	0.89	0.76	0.83	0.94	0.92	0.94
Net Debt	-0.79	-0.44	-0.6	0.3	-0.74	-0.85	-0.66		0.48	-0.92	-0.98	-0.65	-0.53	-0.49	-0.8	-0.76	-0.73	-0.15	-0.77	-0.78	-0.66	-0.25	-0.87	-0.59	-0.8	-0.58
Retained Earnings	-0.8	-0.99	-0.89	-0.09	-0.82	-0.72	-0.88	0.48		-0.25	-0.6	-0.88	-0.89	-0.99	-0.77	-0.74	-0.88	-0.88	-0.89	-0.73	-0.94	-0.93	-0.64	-0.98	-0.78	-0.95
Accounts Payable	0.7	0.23	0.46	-0.46	0.69	0.8	0.55	-0.92	-0.25		0.89	0.56	0.39	0.27	0.72	0.75	0.59	-0.14	0.66	0.7	0.41	-0.02	0.86	0.41	0.72	0.45
Cash	0.88	0.57	0.72	-0.31	0.83	0.91	0.78	-0.98	-0.6	0.89		0.77	0.67	0.62	0.88	0.85	0.83	0.28	0.86	0.86	0.75	0.39	0.92	0.71	0.89	0.7
Non Current Assets Total	0.95	0.88	0.98	-0.3	0.91	0.9	0.99	-0.65	-0.88	0.56	0.77		0.96	0.89	0.93	0.94	0.98	0.66	0.94	0.91	0.85	0.74	0.85	0.93	0.94	0.94
Non Currrent Assets Other	0.89	0.91	0.99	-0.3	0.8	0.79	0.98	-0.53	-0.89	0.39	0.67	0.96		0.91	0.86	0.82	0.95	0.78	0.85	0.88	0.88	0.84	0.72	0.92	0.87	0.9
Other Assets	0.82	1.0	0.91	0.02	0.82	0.72	0.89	-0.49	-0.99	0.27	0.62	0.89	0.91		0.79	0.74	0.88	0.89	0.89	0.77	0.95	0.94	0.66	0.99	0.8	0.96
Cash And Short Term Investments	1.0	0.76	0.89	-0.35	0.94	0.97	0.92	-0.8	-0.77	0.72	0.88	0.93	0.86	0.79		0.96	0.92	0.54	0.94	0.96	0.79	0.63	0.96	0.85	1.0	0.85
Common Stock Total Equity	0.96	0.72	0.86	-0.29	0.96	0.98	0.91	-0.76	-0.74	0.75	0.85	0.94	0.82	0.74	0.96		0.91	0.42	0.93	0.89	0.72	0.52	0.96	0.82	0.96	0.86
Common Stock Shares Outstanding	0.94	0.87	0.97	-0.22	0.89	0.91	0.99	-0.73	-0.88	0.59	0.83	0.98	0.95	0.88	0.92	0.91		0.65	0.94	0.89	0.9	0.73	0.84	0.93	0.93	0.92
Non Current Liabilities Total	0.56	0.9	0.75	0.12	0.52	0.4	0.68	-0.15	-0.88	-0.14	0.28	0.66	0.78	0.89	0.54	0.42	0.65		0.61	0.55	0.8	0.99	0.32	0.81	0.54	0.74
Capital Surpluse	0.95	0.87	0.89	-0.15	0.98	0.94	0.93	-0.77	-0.89	0.66	0.86	0.94	0.85	0.89	0.94	0.93	0.94	0.61		0.89	0.89	0.7	0.91	0.95	0.94	0.96
Other Current Assets	0.97	0.75	0.89	-0.53	0.87	0.9	0.91	-0.78	-0.73	0.7	0.86	0.91	0.88	0.77	0.96	0.89	0.89	0.55	0.89		0.79	0.63	0.92	0.83	0.97	0.83
Other Stockholder Equity	0.81	0.93	0.88	-0.03	0.78	0.73	0.89	-0.66	-0.94	0.41	0.75	0.85	0.88	0.95	0.79	0.72	0.9	0.8	0.89	0.79		0.86	0.68	0.95	0.8	0.91
Total Liab	0.65	0.94	0.82	0.07	0.62	0.5	0.76	-0.25	-0.93	-0.02	0.39	0.74	0.84	0.94	0.63	0.52	0.73	0.99	0.7	0.63	0.86		0.43	0.88	0.63	0.81
Net Invested Capital	0.95	0.63	0.77	-0.37	0.94	0.98	0.83	-0.87	-0.64	0.86	0.92	0.85	0.72	0.66	0.96	0.96	0.84	0.32	0.91	0.92	0.68	0.43		0.76	0.96	0.78
Property Plant And Equipment Gross	0.88	0.98	0.93	-0.07	0.89	0.8	0.94	-0.59	-0.98	0.41	0.71	0.93	0.92	0.99	0.85	0.82	0.93	0.81	0.95	0.83	0.95	0.88	0.76		0.86	0.99
Total Current Assets	1.0	0.77	0.9	-0.35	0.94	0.97	0.92	-0.8	-0.78	0.72	0.89	0.94	0.87	0.8	1.0	0.96	0.93	0.54	0.94	0.97	0.8	0.63	0.96	0.86		0.85
Non Current Liabilities Other	0.87	0.96	0.92	-0.11	0.91	0.82	0.94	-0.58	-0.95	0.45	0.7	0.94	0.9	0.96	0.85	0.86	0.92	0.74	0.96	0.83	0.91	0.81	0.78	0.99	0.85

Click cells to compare fundamentals

IGM Biosciences Account Relationship Matchups

IGM Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	261.4M	408.6M	298.1M	513.5M	423.4M	300.2M
Other Current Liab	3.3M	4.0M	15.6M	27.8M	31.5M	33.1M
Total Current Liabilities	8.9M	17.2M	27.8M	44.7M	42.5M	23.7M
Total Stockholder Equity	(107.2M)	(188.6M)	(353.7M)	(574.8M)	203.2M	213.4M
Net Tangible Assets	240.2M	381.8M	244.9M	287.3M	330.4M	192.1M
Property Plant And Equipment Net	18.0M	34.8M	56.3M	73.1M	74.0M	40.6M
Net Debt	(21.2M)	(228.8M)	(104.6M)	(80.1M)	(72.0M)	(75.6M)
Retained Earnings	(107.2M)	(188.6M)	(353.7M)	(574.8M)	(821.2M)	(780.2M)
Accounts Payable	3.1M	7.9M	5.6M	2.5M	1.3M	1.3M
Cash	35.9M	241.1M	133.3M	121.2M	112.5M	101.6M
Non Current Assets Total	30.3M	35.4M	57.4M	75.1M	75.8M	43.4M
Non Currrent Assets Other	258K	548K	1.0M	2.0M	1.8M	913.3K
Other Assets	258K	548K	1.0M	2.0M	2.3M	2.4M
Cash And Short Term Investments	236.6M	366.3M	229.5M	427.2M	337.7M	251.4M
Common Stock Shares Outstanding	9.0M	30.7M	33.5M	41.5M	52.3M	26.4M
Short Term Investments	188.7M	125.2M	96.2M	305.9M	225.2M	147.9M
Liabilities And Stockholders Equity	(86.1M)	(161.7M)	(300.5M)	(348.6M)	423.4M	444.6M
Non Current Liabilities Total	12.2M	9.6M	25.4M	181.6M	177.7M	186.6M
Capital Surpluse	751K	347.1M	570.0M	598.4M	688.1M	722.5M
Capital Lease Obligations	14.7M	12.2M	28.8M	41.2M	40.5M	21.6M
Other Current Assets	6.4M	14.0M	11.2M	21.3M	9.9M	10.0M
Other Stockholder Equity	(261.7M)	570.0M	598.4M	862.4M	1.0B	1.1B
Total Liab	21.1M	26.8M	53.2M	226.2M	220.2M	231.2M
Net Invested Capital	240.2M	381.8M	244.9M	287.3M	203.2M	197.4M
Property Plant And Equipment Gross	18.0M	34.8M	62.9M	85.4M	94.6M	99.3M
Total Current Assets	231.1M	373.3M	240.7M	438.4M	347.6M	256.8M
Accumulated Other Comprehensive Income	43K	26K	(66K)	(701K)	151K	158.6K
Net Working Capital	222.2M	356.0M	213.0M	393.7M	305.1M	233.1M
Short Term Debt	2.5M	5.3M	6.6M	11.6M	5.8M	5.8M
Common Stock	304K	319K	325K	431K	331K	270.0K
Property Plant Equipment	18.0M	34.8M	28.5M	73.1M	84.0M	88.2M
Short Long Term Debt Total	14.7M	12.2M	28.8M	41.2M	40.5M	26.1M
Capital Stock	304K	319K	325K	431K	586K	361.0K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for IGM Stock Analysis

When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC